SCHEMBL354881

SCHEMBL354881

COc1ccc(OC)c2c1CCC2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 1.00
ALDH1A1 P00352 5/20 1.00
HPGD P15428 3/20 1.00
GLA P06280 1/20 1.00
GAA P10253 1/20 1.00
ACHE P22303 3/20 0.50
HSD17B10 Q99714 1/20 0.46
MAPT P10636 4/20 0.45
NPSR1 Q6W5P4 2/20 0.45
S1PR4 O95977 1/20 0.45
HSP90AA1 P07900 1/20 0.45
G6PD P11413 1/20 0.45
S1PR1 P21453 1/20 0.45
MAPK1 P28482 1/20 0.45
OPRK1 P41145 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
CACNA1B Q00975 1/20 0.45
APBA1 Q02410 1/20 0.45
MCL1 Q07820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30309460 1.00 KDM4E (1.00) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL31597571 0.88 KDM4E (0.79) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL1274261 0.88 KDM4E (0.79) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL3410798 0.86 KDM4E (0.76) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL2722930 0.86 KDM4E (0.76) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL14451818 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL16555954 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL9404807 0.85 ALDH1A1 (0.73) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL11245366 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL31297921 0.85 KDM4E (0.73) KDM4EALDH1A1HPGDGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368001-A1 SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2024-11-07 US disclosed
US-11987506-B2 Salt recovery solution and processes of use thereof AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2024-05-21 US disclosed
US-20230257284-A1 SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2023-08-17 US disclosed
CN-111225875-B Salt recovery solution and method of using salt recovery solution 阿克福特斯技术有限公司 2023-04-11 CN disclosed
US-20230043356-A1 A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2023-02-09 US disclosed
CN-108456531-B Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystal polymer film, retardation film, polarizing plate, and display element 捷恩智株式会社 2023-01-03 CN disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
EP-3946712-A1 A SOLVENT DRYING COMPOSITION AND PROCESSES THERFOR Aquafortus Technologies Limited (NZ) 2022-02-09 EP disclosed
CN-113891760-A Solvent drying compositions and related methods 阿克福特斯技术有限公司 2022-01-04 CN disclosed
US-10844283-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition and liquid crystal polymerized film JNC CORPORATION (JP) 2020-11-24 US disclosed
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2003-06-19 US disclosed
US-6545018-B2 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis PFIZER INC. 2003-04-08 US disclosed
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2002-04-25 US disclosed
US-6326398-B1 Oxamic acids and derivatives as thyroid receptor ligands PFIZER INC. 2001-12-04 US disclosed
EP-1157001-A1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2001-11-28 EP disclosed
WO-2000051971-A1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2000-09-08 WO disclosed
EP-0190740-B1 USE OF SUBSTITUTED QUINONE ELECTRON TRANSFER AGENTS IN ANALYTICAL DETERMINATIONS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1991-11-27 EP disclosed
EP-0399422-A1 Benzocycloalkane derivatives and production thereof Takeda Chemical Industries, Ltd. (JP) 1990-11-28 EP disclosed
US-4746607-A MEDICAL DIAGNOSIS, DETECTION OF BACTERIA EASTMAN KODAK COMPANY (US) 1988-05-24 US disclosed
EP-0190740-A2 Use of substituted quinone electron transfer agents in analytical determinations EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844283-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition and liquid crystal polymerized film NAP1L1, CCNA1, CCNT1 KDM4E 3634/4885ALDH1A1 1548/4885HPGD 3363/4885
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, TSHR KDM4E 4250/4885ALDH1A1 457/4885HPGD 1006/4885
US-20230043356-A1 A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR AQP1, AQP4, NOTUM KDM4E 4279/4885ALDH1A1 3984/4885HPGD 904/4885
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, OXGR1 KDM4E 4496/4885ALDH1A1 553/4885HPGD 1004/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE KDM4E 3495/4885ALDH1A1 2614/4885HPGD 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.